Genetic Rx will take place at Harvard Medical School and will bring together academics, key industry leaders and investors to discuss the emergence of new genetic medicines as well as the treatment of patients with rare and ultra-rare genetic diseases.

Speakers and Co-Hosts Include:
Sudhir Agrawal, President of Research, Idera Pharmaceuticals; Tom Barnes, CSO, Intellia Therapeutics; Paul Bolno, President & CEO, WAVE Life Sciences; PJ Brooks, Program Director, NIH; Belen Carillo-Rivas, Global Clinical Submission Lead, Pfizer; Stacy Coen, Head, Rare Disease BD&L, Sanofi Genzyme; Olivier Danos, SVP, Cell & Gene Therapy, Biogen; Oliver Fetzer, CEO, Synthetic Genomics; Terence Flotte, Dean, UMass Medical School; Sandra Glucksmann, COO, Editas Medicine; JC Gutierrez-Ramos, CEO, Synlogic Therapeutics, Kathy High, President & CSO, Spark Therapeutics; James Jenson, CEO, CytoSite BioPharma; Edward Kaye, CEO, Sarepta; Sven Kili, Head of Cell & Gene Therapy R&D, GlaxoSmithKline; Greg LaRosa, VP, CSO, Pfizer; Bill Lundberg, CSO, CRISPR Therapeutics; Sandy Macrae, President & CEO, Sangamo BioSciences; Ivana Magovcevic-Liebisch, SVP & Head of Global BD, Teva; Christian Meyer, CMO, uniQure; Walter Ogier, President & CEO, Acetylon; Ed Pezalla, former National Medical Director, Pharmaceutical Policy & Strategy, Aetna; Jude Samulski, CSO & VP, Gene Therapy, Bamboo Therapeutics; Paula Soteropoulos, CEO, Akcea Therapeutics; Arthur Tzianabos, CEO, Homology Medicines; Sue Washer, CEO, AGTC